Bliss GVS Pharma Limited, a prominent player in the pharmaceutical industry, announced a significant change in its leadership. The company's Managing Director, Gagan Harsh Sharma (DIN: 07939421), has resigned from his position, effective immediately from November 6, 2025.

Resignation Details

The Board of Directors of Bliss GVS Pharma Limited convened a meeting at the company's registered office on November 6, 2025, where they accepted Mr. Sharma's resignation. Mr. Sharma cited other professional commitments as the reason for his departure.

Impact on Company Positions

As a result of his resignation, Mr. Sharma will also step down from several key positions within the company:

Additionally, Mr. Sharma has relinquished his directorship roles in the following subsidiary and associate companies:

• Kremoint Pharma Pvt. Ltd.
• Bliss GVS International Pte Ltd (Singapore)
• Asterisk Life Sciences Ghana Ltd
• EPII Exports Pvt. Ltd.
• Asterisk Lifesciences GB Limited (UK)

Family Connections

Mr. Sharma has familial ties within the company's leadership:

• Spouse of Dr. Vibha Sharma, Whole-Time Director
• Brother-in-law of Mrs. Shruti Vishal Rao, also a Whole-Time Director

Other Board Decisions

In the same board meeting, which lasted from 4:30 PM to 6:10 PM, the company also:

• Approved the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2025
• Appointed Mr. Shreekrushna Joshi as Head – Legal and Senior Management Personnel, effective from November 6, 2025

The company has informed the National Stock Exchange of India Ltd. and BSE Limited about these developments, in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

As Bliss GVS Pharma Limited navigates this transition in leadership, stakeholders will be observing how these changes may impact the company's future direction and performance in the pharmaceutical sector.

Bliss GVS Pharma Limited , a prominent player in the Indian pharmaceutical sector, has taken a significant step to incentivize its workforce. The company's Nomination and Remuneration Committee approved the grant of 5,53,000 stock options to eligible employees under its Employee Stock Options Plan 2019.

Key Details of the Stock Option Grant

Vesting and Exercise Details

The stock options will vest in four equal installments over four years, with each tranche representing 25% of the total granted options. This staggered vesting schedule aims to promote long-term employee retention and align employee interests with those of the company's shareholders.

Once vested, employees will have a window of six months to exercise their options.

Potential Impact on Employee Retention and Motivation

By offering these stock options at a substantial discount of 72.05% to the market price, Bliss GVS Pharma is providing a potentially lucrative opportunity for its employees. This move may serve to:

1. Enhance employee loyalty and retention
2. Align employee interests with company performance
3. Attract top talent in a competitive pharmaceutical industry

Additional Corporate Updates

Bliss GVS Pharma also announced significant changes in its leadership:

1. Resignation of Managing Director: Mr. Gagan Harsh Sharma has resigned from his position as Managing Director, effective immediately, citing other professional commitments.

2. New Senior Management Appointment: Mr. Shreekrushna Joshi has been appointed as Head – Legal and designated as Senior Management Personnel, bringing over 15 years of experience in corporate legal and secretarial compliance.

These changes in the company's leadership structure, coupled with the employee stock option grant, signal a period of transition for Bliss GVS Pharma.